Compare · AZN vs RNA
AZN vs RNA
Side-by-side comparison of AstraZeneca PLC (AZN) and Atrium Therapeutics Inc. (RNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and RNA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 1932.3x RNA ($133.8M).
- Over the past year, AZN is up 97.3% and RNA is down 84.3% - AZN leads by 181.6 points.
- AZN has been more active in the news (18 items in the past 4 weeks vs 12 for RNA).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Atrium Therapeutics Inc.
- Price
- $165.42-0.74%
- $7.68-1.60%
- Market cap
- $258.47B
- $133.8M
- 1M return
- -0.43%
- -19.49%
- 1Y return
- +97.30%
- -84.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 18
- 12
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Atrium Therapeutics Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC
Latest RNA
- Amendment: SEC Form 8-K/A filed by Atrium Therapeutics Inc.
- SEC Form 8-K filed by Atrium Therapeutics Inc.
- Atrium Therapeutics Announces $50 Million Private Placement
- Chief Scientific Officer Younis Husam covered exercise/tax liability with 11,216 shares, decreasing direct ownership by 21% to 41,441 units (SEC Form 4) to cover taxes
- Chief Medical Officer Hughes Steven George covered exercise/tax liability with 21,459 shares, decreasing direct ownership by 29% to 51,638 units (SEC Form 4) to satisfy withholding tax
- Director Boyce Sarah covered exercise/tax liability with 126,418 shares, decreasing direct ownership by 48% to 138,668 units (SEC Form 4) (withholding obligation)
- Director Flanagan W. Michael covered exercise/tax liability with 22,812 shares, decreasing direct ownership by 42% to 31,974 units (SEC Form 4) to satisfy withholding tax
- Officer Kenney Stephanie covered exercise/tax liability with 2,375 shares, decreasing direct ownership by 7% to 33,085 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Winslow Brendan R. covered exercise/tax liability with 6,742 shares, decreasing direct ownership by 15% to 36,859 units (SEC Form 4) (for withholding tax)
- Officer Gallagher Kathleen P. covered exercise/tax liability with 11,632 shares, decreasing direct ownership by 9% to 119,729 units (SEC Form 4) (for tax liability)